Thai investigators test a botanical emulgel formulation to identify early safety signals related to skin irritation and allergenicity before advancing to patient trials.
Patients with psoriatic arthritis consistently identify nonjoint symptoms such as dactylitis, psoriasis, and uveitis, demonstrating the clinical utility of patient-reported outcome measures.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
This clinical trial summary highlights the efficacy, safety, and sustained scalp clearance achieved with guselkumab for moderate to severe scalp psoriasis in patients with skin of color.
French researchers in JAMA Dermatology linked high ultraprocessed food consumption to increased rates of psoriasis, emphasizing the need for further investigation.